TP53 and cyclic hematopoiesis: While emerging data have suggested that IMiD therapy may promote selection and clonal evolution of secondary myeloid neoplasms in specific cases, namely in patients with TP53-mutant CH (56), our data would suggest that most patients with CH benefit from IMiD-based therapy.